KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Debt to Equity (2016 - 2026)

Pfizer has reported Debt to Equity over the past 18 years, most recently at $0.72 for Q1 2026.

  • Quarterly Debt to Equity rose 4.39% to $0.72 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $0.72 through Mar 2026, up 4.39% year-over-year, with the annual reading at $0.75 for FY2025, 3.7% up from the prior year.
  • Debt to Equity was $0.72 for Q1 2026 at Pfizer, down from $0.75 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.81 in Q4 2023 and troughed at $0.35 in Q2 2023.
  • The 5-year median for Debt to Equity is $0.69 (2025), against an average of $0.63.
  • Year-over-year, Debt to Equity tumbled 64.38% in 2022 and then soared 115.54% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $0.37 in 2022, then soared by 115.54% to $0.81 in 2023, then dropped by 10.25% to $0.72 in 2024, then increased by 3.7% to $0.75 in 2025, then fell by 4.53% to $0.72 in 2026.
  • Per Business Quant, the three most recent readings for PFE's Debt to Equity are $0.72 (Q1 2026), $0.75 (Q4 2025), and $0.66 (Q3 2025).